Analyst Salim Syed from Mizuho Securities assigned a Buy rating on Biogen (BIIB – Research Report) and keeping the price target at ...

The Cambridge company's experimental drug was being evaluated in a Phase 2 study in people with mild cognitive impairment in ...

The Cambridge-based developer of the first oral medication to treat postpartum depression surprised analysts with higher-than ...

Biogen maintained its 2024 adjusted EPS guidance of $15 to $16, compared with the Capital IQ-polled consensus of $15.48. The company continues to expect a a low- to mid-single digit drop in revenue as ...

Biogen Inc. (NASDAQ: BIIB), a leading biotechnology company, has released its Q1 2024 financial results, showcasing ...

Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line.

If you think about it, many of today’s high-flying stocks were once ignored by the Street. Nvidia (NASDAQ:NVDA) was a ...

Primecap is an investment firm founded in 1983. They became well-known for their managing US-equity portfolio for the giant Vanguard. In 2004 they launched their mutual funds. The firm always had a ...

Sage Therapeutics said on Wednesday it would stop working on its experimental drug for Parkinson's disease after the ...

Nasdaq 100 E-Mini futures (NQM24) are trending up +0.53% this morning as Tesla surged on new EV promises and investors looked ...